Published research

Peer-Reviewed Publications using Premier/i3 Linked Data

  1. Ernst FR, Davis TE, Ryan AC, Stemkowski S. Linkage of a multi-hospital database to health plan claims data for continuum of care outcomes research [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL, May 2009.
  2. Henk H, McDonald HP, Borah BJ, Nelson M (non-Premier authors). Evaluation of continuity of care between inpatient and outpatient settings via administrative claims databases using the example of VTE prophylaxis in total hip and total knee replacement. [Workshop W34]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL, May 2009.
  3. Stensland MD, Peng X (non-Premier authors). Continuity of care following hospitalization for bipolar disorder in private payer claims [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL, May 2009.

Peer-Reviewed Publications using Premier’s Perspective™ Data

CARDIOVASCULAR DISEASE

  1. Amin A, Hussein M, Battleman D, Lin J, Stemkowski S, Merli GJ. Appropriate VTE prophylaxis is associated with lower direct medical costs among medical and surgical patients in the United States [Abstract]. American Society of Hematology (ASH), San Francisco, CA, December 2008.
    View abstract
  2. Amin A, Lin J (non-Premier authors). Hospital-acquired venous thromboembolism rates following prophylaxis with enoxaparin and dalteparin [Abstract]. American College of Chest Physicians (CHEST), San Diego, CA, November 2009.
  3. Amin A, Lin J, Ryan AC. VTE prophylaxis patterns across the continuum of care in US cancer patients [Abstract]. American Society of Clinical Oncology (ASCO), Orlando, FL, May-June 2009.
    4. M
  4. 4. Amin A, Lin J, Ryan AC. Analysis of inpatient and outpatient venous thromboembolism prophylaxis patterns in US critical care patients [Abstract]. American College of Chest Physicians (CHEST), San Diego, CA, November 2009.
  5. Amin A, Lin J, Ryan AC. VTE prophylaxis across the continuum of care in US medical patients at risk of venous thromboembolism [Abstract]. American Society of Hematology (ASH), New Orleans, LA, December 2009.
  6. Amin A, Lin J, Ryan AC. VTE prophylaxis across the continuum of care in US orthopedic surgery patients [Abstract]. American Society of Hematology (ASH), New Orleans, LA, December 2009
  7. Amin A, Lin J, Ryan AC. VTE prophylaxis across the continuum of care in US medical and surgical patients at risk of venous thromboembolism [Abstract]. American College of Chest Physicians (CHEST), San Diego, CA, November 2009.
  8. 8Amin A, Lin J, Yang G, Stemkowski S. Are there any differences in the clinical and economic outcomes between US cancer patients receiving appropriate or inappropriate venous thromboembolism prophylaxis? J Onc Pract 2009; 5(4): 159-64.
  9. Amin A, Stemkowski S, Lin J, Yang G. Appropriate prophylaxis in hospitalized cancer patients. Clin Adv Hematol Oncol 2008; 6(12): 610-20.
  10. Amin A, Stemkowski S, Lin J, Yang G. Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? J Thromb Haemost 2008; 99(4): 796-7.
  11. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis compliance in US hospitals: adherence to the sixth American College of Chest Physicians’ recommendations for at-risk medical patients [Podium]. CHEST, Orlando, FL, October 2006. [CHEST 2006; 130(4 Suppl): 87S.] Alfred Soffer Research Award Winner
  12. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis in US hospitals: adherence to the sixth American College of Chest Physicians’ recommendations for at-risk medical and surgical patients [Abstract]. Am Society of Health-System Pharmacists (ASHP) Mid-Year Meeting, Anaheim, CA, December 2006.
  13. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis in US hospitals: adherence to the seventh American College of Chest Physicians’ recommendations for at-risk medical and surgical patients. J Hosp Med 2009; 4(8): E15-E21.
  14. Amin A, Stemkowski S, Lin J, Yang G. Assessing adherence to the American College of Chest Physicians’ (ACCP) recommendations for thromboprophylaxis in hospitalized acute medical patients [Podium]. Society for General Internal Medicine (SGIM), Toronto, Ontario, Canada, April 2007.
  15. Amin A, Stemkowski S, Lin J, Yang G. Assessing adherence to the ACCP recommendations for thromboprophylaxis in hospitalized medical and surgical patients [Abstract]. Society for Hospital Medicine (SHM) Annual Meeting, Dallas, TX, May 2007.
  16. Amin A, Stemkowski S, Lin J, Yang G. Assessing adherence to the American College of Chest Physicians’ (ACCP) recommendations for thromboprophylaxis in hospitalized cancer patients [Abstract]. American Society of Clinical Oncology (ASCO), Chicago, IL, June 2007.
  17. Amin A, Stemkowski S, Lin J, Yang G. Clinical and economic outcomes following full or partial ACCP recommended prophylaxis in cancer patients at- risk or venous thromboembolism [Abstract]. American Society of Hematology (ASH), San Francisco, CA, December 2008.
  18. Amin A, Stemkowski S, Lin J, Yang G. Rates of Guideline-Recommended Venous Thromboembolism Prophylaxis in US Hospital Patients [Abstract]. Society of Hospital Medicine (SHM), April, 2008, San Diego, CA.
  19. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost 2007; 5: 1610-6.
  20. Amin A, Stemkowski S, Lin J, Yang G. Using administrative hospital data to assess outcome variation in acute medical and surgical at-risk for venous thromboembolism across anti-coagulation regimens: an analytic design [Podium]. American Federation for Medical Research (AFMR) Western Regional Meeting, Carmel, CA, January/February 2007.
  21. Amin A, Stemkowski S, Lin J, Yang G. VTE Prophylaxis in US Hospitals [Abstract]. American Heart Association (AHA): Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference, Washington DC, May 2007.
  22. Amin A, Stemkowski S, Lin J, Yang G. VTE prophylaxis use in severe lung disease patients [Abstract]. American Thoracic Society (ATS), Toronto, Ontario, Canada, May 2008.
  23. Auerbach AD, Hilton JF, Maselli J, Pekow PS, Rothberg MB, and Lindenauer PK (non-Premier authors). Shop for quality or volume? volume, quality, and outcomes of coronary artery bypass surgery. Ann Intern Med 2009; 150: 696-704.
  24. Belz M, Spalding JR, Exuzides A, Adams S, Colby C, Noe LL, Neil N (non-Premier authors). Likelihood and cost of adverse events in atrial fibrillation are associated with choice of acute conversion therapy [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Ontario, Canada, May 2008 (Value Health 2008; 11(3): A200).
  25. Boccuzzi SJ, Martin J, Stephenson J, Kreilick C, Fernandes J, Beaulieu J, Hauch O, Kim J. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed. Current Medical Research & Opinion (CMRO) 2009; 25(12); 2853-64
  26. Deitelzweig SB, Lin,J, Hussein M, Battleman D (non-Premier authors). Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis? J Thromb Thrombolysis 2009 (Epub ahead of print)
  27. 27. Deitzelweig S, Lin J, Hussein M, Battleman D (non-Premier authors). Are surgical patients at risk of venous thromboembolism currently meeting the surgical care improvement performance target goal for appropriate and timely prophylaxis? [Abstract]. CHEST, Philadelphia, PA, October 2008.
  28. DiDomenico R, Sengupta N, Barker C (non-Premier authors). Impact of nesiritide on treatment of acute decompensated heart failure (ADHF): evidence form a US hospital database [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, May 2007. [Value Health 2007; 10(3): A47.] Best Poster Presentation Award Recipient
  29. Happe LE, Rao SV, Horblyuk R, Franklin M, Lunacsek OE, Menditto L (non-Premier authors). Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants. Curr Med Res Opin (CMRO) 2009; 25(2): 413-20.
  30. Huang X, Gondek K, Smith P (non-Premier authors). Variation of cost-to-charge ratio for CABG patient by hospital type over time [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2006, Philadelphia, PA [Value Health 2006; 9(3): A130-A131]
  31. Kessler DP (non-Premier author). Effect of bivalirudin on clinical outcomes of STEMI patients in an observational dataset [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010. [Value Health 2010; 13(3): A149]
  32. Kessler DP (non-Premier author). Effect of bivalirudin on economic outcomes of STEMI patients in an observational dataset [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010. [Value Health 2010; 13(3): A11]
  33. Kim MH, Klingman D, Lin J, Pathak P, Battleman DS (non-Premier authors). Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann Pharmacother 2009;
    43(5): 840-xxx (online ahead of print: www.theannals.com/cgi/content/abstract/43/5/840).
  34. Krishnan S, Conner TM, Leslie R, Stemkowski S, Shander A. Choice of hemostatic agent and hospital length of stay in cardiovascular surgery. Semin Cardiothorac Vasc Anesth 2009; (Epub ahead of print, doi:10.1177/1089253209351321).
  35. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM (non-Premier authors). Lipid-lowering Therapy and In-Hospital Mortality Following Major Noncardiac Surgery. JAMA. 2004; 2092-2099.
  36. Merli GJ, Ferrufino C, Lin J, Hussein M, Battleman D (non-Premier authors). Total hospital-based costs of enoxaparin or fondaparinux prophylaxis in patients at risk of venous thromboembolism (Abstract]. CHEST, Philadelphia, PA, October 2008.
  37. Merli GJ, Ferrufino CP, Lin J, Hussein M, Battleman D (non-Premier authors). Low-molecular-weight heparin reduces the cost of venous thromboembolism treatment compared with unfractionated heparin in US hospitals [Abstract]. American Society of Hematology (ASH), Atlanta, GA, December, 2007 (Blood 2007; 110(11): #1860).
  38. Nickman NA, Biskupiak J, Creekmore F, Shah H, Brixner DI (non-Premier authors). Antiplatelet medication management in patients hospitalized with ischemic stroke. Am J Health-Syst Pharm 2007; 64(21): 2250-6.
  39. Pineo G, Lin J, Stern L, Subrahmanian T (non-Premier authors). Enoxaparin is cost-saving compared with unfractionated heparin (UFH) for venous thromboemobolism prophylaxis in patients with acute ischemic stroke: an analysis of hospital costs from the PREVAIL trial [Abstract]. International Society on Thrombosis and Haemostasis (ISTH), Boston, MA, July 2009.
  40. Pineo G, Lin J, Stern L, Subrahmanian T (non-Premier authors). Enoxaparin is cost-saving compared with unfractionated heparin (UFH) for venous thromboemobolism prophylaxis in patients with acute ischemic stroke: an analysis of hospital costs from the PREVAIL trial [Abstract]. International Society on Thrombosis and Haemostasis (ISTH), Boston, MA, July 2009.
  41. Rassen JA, Mittleman MA, Glynn RJ, Brookhart MA, Schneeweiss S (non-Premier authors). Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J 2009 (Published online - doi:10.1093/eurheart/ehp437).
  42. Schneeweiss S, Seeger JD, Landon J, Walker AM (non-Premier authors). Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death. N Engl J Med 2008; 358(8): 771-83.
  43. Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E (non-Premier authors). Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. Am J Health-Syst Pharm 2007; 64(22): 2349-55.
  44. Simpson RJ, Ryan AC, Kuznik A. Dosage patterns in two cohorts of hospitals primarily using atorvastatin or simvastatin among inpatients with acute coronary syndrome [Abstract]. American Hospital Association (AHA) Quality of Care and Outcomes Research (QCOR) in Cardiovascular Disease and Stroke Conference, Washington, DC, April 2009.
    View abstract
  45. Spalding J, Exuzides A, Colby C, Neil N, Noe L (non-Premier authors). Inpatient resource use among patients treated for primary atrial fibrillation (AF): role of clinical factors and choice of initial conversion therapy [Abstract]. ISPOR, Orlando, FL, May 2009. [Value Health 2009; 12(3): A153]
  46. Spalding J, Exuzides A, Colby C, Neil N, Noe L (non-Premier authors). Management of primary atrial fibrillation (AF): patient characteristics and hospital care setting [Abstract]. ISPOR, Orlando, FL, May 2009. [Value Health 2009; 12(3): A153]
  47. Suri MFK, Vazquez G, Ezzeddine MA, Qureshi AI (non-Premier authors). A multicenter comparison of outcomes associated with intravenous nitroprusside and nicardipine treatment among patients with intracerebral hemorrhage. Neurocrit Care 2009; 11(1): 50-5.
  48. Wang F, Iyer S, Ciuryla V, Feng Wang P. Impact of ventricular arrhythmia on mortality, health care utilization and costs in hospitalized acute myocardial infarction patients [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2006, Philadelphia, PA [Value Health 2006; 9(3): A19-A20]

DIABETES

  1. Yurgin N, Foster S, Ernst FR, Iorga S, Halpern R. Resource utilization and costs of diabetes patients compared with non-diabetes patients in the hospital and outpatient settings [Abstract]. American Diabetes Association (ADA), New Orleans, LA, June 2009.

GASTROINTESTINAL DISORDERS

  1. Iyer S, Saunders W. Burden of post-operative ileus (POI) in colectomy surgery patients [Encore abstract]. American College of Clinical Pharmacy (ACCP), Denver, CO, October 2007.
  2. Iyer S, Saunders W. Burden of post-operative ileus (POI) in colectomy surgery patients in the United States [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, May 2007. [Value Health 2007; 10(3): A148.]
  3. Iyer S, Saunders W. Impact of post-operative ileus (POI) on hospital length of stay in colectomy surgery patients [Abstract]. American College of Gastroenterology (ACG), Philadelphia, PA, October 2007.
  4. Iyer S, Saunders WB, Stemkowski S. Economic burden of postoperative ileus associated with colectomy in the United States. J Managed Care Pharm (JMCP) 2009; 15(6): 485-94.
  5. Mahmoud N, Turpin RS, Saunders W. Surgical site infections, length of stay and costs associated with 23,067 colorectal procedures [Abstract]. American Society of Colon and Rectal Surgeons (ASCRS), Louis, MO, June 2007.
  6. Saunders WB, Bowers B, Moss B, Wang PF. Recorded Rate and Economic Burden Associated with Postoperative Ileus [Abstract]. American Society for Health-System Pharmacists (ASHP), Orlando, FL, December 2004.
  7. Senagor A, Delaney C, Wang PF, Saunders WB, Matuszewski K, Moss B, Bell T, Fort J (for the Alvimopan Postoperative Ileus Study Group). Economic burden and risk factors associated with ICD-9 coded postoperative ileus (POI): Results from US hospital data during 2002 [Abstract]. American Society of Colon & Rectal Surgeons (ASCRS), April/May, 2005.
  8. Wang PF, Bowers B, Moss B, Bell TJ, Saunders WB. Economic Burden of Illness Associated with Coded Postoperative Ileus after Open Laparotomies [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Washington, DC, May 2005. [Value Health 2005; 8(3): A338].

HEMATOLOGY

  1. Duh M, Vekeman F, McKenzie RS, Lefebvre P, Watson S, Mody S, Piech CT (non-Premier authors). Comparison of epoetin alfa and darbepoetin alfa treatment costs in an inpatient oncology setting [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2006, Philadelphia, PA [Value Health 2006; 9(3): A19]
  2. Duh M, Vekeman F, McKenzie RS, Lefebvre P. Watson S, Mody S, Piech CT (non-Premier authors). Real-world epoetin alfa (Epo) and darbepoetin alfa (Darb) dosing and cost considerations in elderly hospital inpatients: results from a large observational study [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, May 2007. [Value Health 2007; 10(3): A131.]
  3. Jurss L, Craver C, Nordyke R. Impact of reimbursement changes for erythropoiesis-stimulating agents (ESAs) on hospital transfusion trends in patients with cancer: an administrative data comparison between 2006 and 2007 [Abstract]. American Society of Health-System Pharmacists (ASHP), Orlando, FL, December 2008.
    View poster
  4. Lafeuille MH, Bailey R, Vekeman F, Piech CT, McKenzie RS, Lefebvre P (non-Premier authors). Recent erythropoiesis-stimulating agent (ESA) utilization trend in cancer chemotherapy patients in a managed care and a hospital outpatient setting [Abstract]. ISPOR, Orlando, FL, May 2009. [Value Health 2009; 12(3): A2].
  5. Maxon MS, Russell AB, Wisont K, Stemkowski S, Johnson BH, Rodgers GM. A novel approach for estimating resource utilization in patients with suspected immune-mediated coagulopathy associated with exposure to topical bovine thrombin [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010. [Value Health 2010; 13(3): A103]
  6. Stokes M, Ye X, Mercaldi K, Reynolds MW, Rupnow MF, Hammond J (non-Premier authors). Impact of bleeding-related complications and blood product transfusions on hospital length of stay and costs in inpatient surgical patients [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010. [Value Health 2010; 13(3): A102]
  7. Suri MFK, Vazquez G, Ezzeddine MA, Qureshi AI (non-Premier authors). A multicenter comparison of outcomes associated with intravenous nitroprusside and nicardipine treatment among patients with intracerebral hemorrhage. Neurocrit Care 2009; 11(1): 50-5.
  8. Vekeman F, Bailey R, Lafeuille MH, McKenzie RS, Herrera AD, Lefebvre P (non-Premier authors). Comparison of epoetin alfa and darbepoetin alfa dosing patterns and costs in cancer inpatients receiving chemotherapy [Abstract]. ISPOR, Orlando, FL, May 2009. [Value Health 2009; 12(3): A40-41].
  9. Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS (non-Premier authors). Dose and cost comparison of erythropoietic agents in the inpatient hospital setting [Abstract]. Society of Critical Care Medicine (SCCM), San Francisco, CA, January 2006.
  10. Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS (non-Premier authors). Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Am J Health-Syst Pharm 2007; 64(18): 1943-9.
  11. Wang PF, Saunders W, Gaylord B, Vardireddy N. A Hidden Epidemic among Acute Care Inpatients: Economic and Clinical Impacts of Anemia in Selected Chronic Diseases [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Washington, DC, May 2005. [Value Health 2005; 8(3): A282].
  12. Wang PF, Saunders WB, Vardireddy N, Gaylord B. Managing Anemia Among Hospitalized Patients With Chronic Diseases: A Retrospective Analysis Of The Cost And Effectiveness Of Using Erythropoietin [Abstract]. Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, American Heart Association, May 2005.
  13. Yank V, Tuohy CV, Logan A, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS (non-Premier authors). The safety and efficacy of recombinant activated factor VIIa for cardiac surgery: patterns of use and comparative effectiveness review [Abstract]. Society for Medical Decision Making (SMDM), Hollywood, CA, October 2009.
  14. Yank V, Tuohy CV, Logan A, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS (non-Premier authors). The safety and efficacy of recombinant activated factor VIIa for non-traumatic intracranial hemorrhage: patterns of use and comparative effectiveness review [Abstract]. Society for Medical Decision Making (SMDM), Hollywood, CA, October 2009.
  15. Yank V, Tuohy CV, Logan A, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS (non-Premier authors). The safety and efficacy of recombinant activated factor VIIa for cardiac surgery: patterns of use and comparative effectiveness review [Abstract]. Society for Medical Decision Making (SMDM), Hollywood, CA, October 2009.
  16. Yank V, Tuohy CV, Logan A, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS (non-Premier authors). The safety and efficacy of recombinant activated factor VIIa for non-traumatic intracranial hemorrhage: patterns of use and comparative effectiveness review [Abstract]. Society for Medical Decision Making (SMDM), Hollywood, CA, October 2009.

HYPONATREMIA

  1. Ernst FR, Seal B, Richmond M. Greater severity of illness, risk of mortality, length-of-stay and hospital costs in patients with hyponatremia versus without hyponatremia [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Ontario, Canada, May 2008. [Value Health 2006; 11(3): A161-2]

INFECTION / INFECTIOUS DISEASE

  1. Benson C, Schein JR, Grant R, Mody S, Olson W. (non-Premier authors). Length of stay in hospitalized community-acquired pneumonia (CAP) patients treated with levofloxacin 750 mg IV or Moxifloxacin 400 mg IV [Abstract]. American Thoracic Society (ATS), Toronto, Ontario, Canada, May 2008.
  2. Canada TW, Turpin RS, Williams K, Scott S (non-Premier authors). Blood-stream infections and their attributable length of stay: does delivery of parenteral nutrition via multi-chamber bag have any impact? [Abstract] American College of Clinical Pharmacy (ACCP), Anaheim, CA, October 2009.
  3. Carson JG, Turpin RS, Hu H, Ma L, Wilson SE (non-Premier authors). Cost analysis of five antimicrobial regimens in the treatment of intra-abdominal infection. Surg Infect 2008; 9(1): 15-21.
  4. Carson JG, Turpin RS, Hu H, Ma L, Wilson SE (non-Premier authors). Cost analysis of treatment of intra-abdominal infection with five antimicrobial regimens [Abstract]. Surgical Infection Society – Europe, May 2006, Athens, Greece.
  5. Chandwani S, Wentworth C, Burke T, Patterson TF (non-Premier authors). Utilization of echinocandins for treatment of fungal infections in US hospital practice – a descriptive analysis [Abstract]. Focus on Fungal Infections 18, March 2008, San Antonio, TX.
  6. Chandwani S, Wentworth C, Burke T, Patterson TF (non-Premier authors). Utilization of echinocandins for treatment of fungal infections in US hospital practice. Curr Med Res Opin (CMRO) 2009; 25(2): 385-93.
  7. Chang S-C, Melnick DA, Soto N, Iaconis J, Hirsch MW, Yang H (non-Premier authors). Disease burden and trend of hospitalized pneumonia in the US from 2004 to 2008 [Abstract]. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, September 2010 (Submitted).
  8. Craver CW, Blanchette CM, Gasper S. Cost and outcomes associated with fluconazole treatment failure for invasive Candida infection in hospitalized patients [Abstract]. Am Society of Health-System Pharmacists (ASHP) Mid-Year Meeting, Anaheim, CA, December 2006.
    View abstract
  9. Craver CW, Tarallo M, Roberts CS, Blanchette CM, Ernst FR. Cost and outcomes associated with fluconazole as first-line therapy for invasive candidiasis. Clin Ther 2010 (In press).
  10. Eagye KJ, Nicolau DP. (non-Premier authors). Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol 2010; 31(5): 485-90.
  11. Eagye KJ, Nicolau DP. (non-Premier authors). Change in anti-pseudomonal carbapenem susceptibility (ACS) in 25 hospitals is not associated with the use of ertapenem (ERT) [Abstract]. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 2009.
  12. Eagye KJ, Nicolau DP. (non-Premier authors). Fluoroquinolone (FQ) Use Is Not Associated with Change in Imipenem (IMP) Susceptibility of Pseudomonas aeruginosa (PSA) in 24 Hospitals [Abstract]. Infectious Disease Society of America (IDSA), Philadelphia, PA, October 2009.
  13. Edmiston CE, Seabrook GR, Patkar AD, Magee G, Vaughn B. Use of an observational, nationwide inpatient discharge database to document the economic benefits associated with innovative antimicrobial technology to reduce the risk of surgical site infection (SSI) [Abstract]. Association for Professionals in Infection Control and Epidemiology (APIC), New Orleans, LA, July 2010.
  14. Friedman H, Song X, Crespi S, Navaratnam P (non-Premier authors). Similar lengths of stay and hospital costs for patients with community-acquired pneumonia treated with intravenous moxifloxacin 400 mg or levofloxacin 750mg [Abstract]. CHEST, Philadelphia, PA, October 2008.
  15. Friedman H, Song X, Crespi S, Navaratnam P (non-Premier authors). Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia. Value Health 2009 (Epub ahead of print).
  16. 76. Hashemi L, Ernst FR, Minshall M. The incidence and cost of surgical site infections (SSIs) in common obstetric and gynecologic procedures in the USA: a study using the Premier Perspective™ Database (PPD). Society of Gynecologic Oncologists (SGO) [Abstract]. San Francisco, CA, March 2010.
  17. Hashemi L, Minshall M (non-Premier authors). The incidence and cost of surgical site infections (SSIs) in common knee and hip procedures in the USA: a study using the Premier Perspective™ Database (PPD) [Abstract]. American college of Surgeons (ACS), Washington, DC, October 2010 (Accepted).
  18. Janagap C, Schein JR, Sikirica V, Doshi D, Martinez F (non-Premier authors). Comparison of demographics, length of stay, and resource utilization in hospitalized community-acquired pneumonia (CAP) patients treated with levofloxacin or moxifloxacin [Abstract]. American Society of Health-System Pharmacists (ASHP) Midyear Meeting, Anaheim, CA, December 2006.
  19. Liu FX, Mercaldi K, Reynolds MW, Turpin R (non-Premier authors). Methods to identify and compare bloodstream infection rates among patients administered parenteral nutrition via hospital compounded vs. premixed multichamber bags [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010. [Value Health 2010; 13(3): A195]
  20. Mahmoud N, Turpin RS, Saunders W. Surgical site infections, length of stay and costs associated with 23,067 colorectal procedures [Abstract]. American Society of Colon and Rectal Surgeons (ASCRS), Louis, MO, June 2007.
  21. Mahmoud NN, Turpin RS, Yang G, Saunders WB. Impact of surgical site infections on length of stay and costs in selected colorectal procedures. Surg Infect (Larchmt) 2009; 10(6): 539-44.
  22. Minshall M, Ernst FR, Hashemi L. The incidence and cost of surgical site infections (SSIs) in common cardiothoracic surgical procedures in the USA: a study using the Premier Perspective™ Database (PPD) [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010 [Value Health 2010; 13(3): A159]
  23. Neslusan C, Nuyts G, Stellhorn R (non-Premier authors). The impact of mechanical ventilation on outcomes and costs in nosocomial pneumonia [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2006, Philadelphia, PA [Value Health 2006; 9(3): A156-A157]
  24. Orrick JJ, Segal R, Johns TE, Russell W, Wang PF, Yin DD. Resource Use and Cost of Care for Patients Hospitalised with Community Acquired Pneumonia: Impact of Adherence to Infectious Diseases Society of America Guidelines. Pharmacoeconomics 2004; 22(11):751-757.
  25. Patel DA, Gao X, Stephens JM, Forshag MS, Tarallo (non-Premier authors). Clinical and economic outcomes of invasive aspergillosis (IA) in the chronic obstructive pulmonary disease (COPD) non-traditional host: a hospital database analysis [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010. [Value Health 2010; 13(3): A188]
  26. Pontes-Arruda A, Turpin R, Williams K, Reynolds M, Zaloga G (non-Premier authors). Blood-stream infection rates in manufactured premix and compounded parenteral nutrition [Abstract]. World Federation of Societies of Intensive and Critical Care Medicine (WFSICCM), Florence, Italy, August 2009 (Accepted).
  27. Rassen JA, Mittleman MA, Glynn RJ, Brookhart MA, Schneeweiss S (non-Premier authors). Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J 2009 (Published online - doi:10.1093/eurheart/ehp437).
  28. Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W (non-Premier authors). A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Current Med Res Opin 2008; 24(3):895-90.
  29. Schein JR, Janagap C, Grant R, Sikirica V, Doshi D, Olson W (non-Premier authors). Outcomes associated with levofloxacin and moxifloxacin in hospitalized community-acquired pneumonia (CAP) patients [Abstract]. American Thoracic Society (ATS), San Francisco, CA, May 2007.
  30. Scherer LA, Turpin RS, Williams K, Stephen R, Schermer CR (non-Premier authors). Bloodstream infections in patients receiving manufactured premix parenteral nutrition with and without lipids: are the new nutrition support guidelines appropriate? [Abstract]. American Association for the Surgery of Trauma (AAST), Pittsburgh, PA, October 2009. 
    View abstract
  31. Sikirica V, Janagap C, Grant R, Crown WH, Olson W, Schein JR (non-Premier authors). Total and departmental costs and length of stay in hospitalized community-acquired pneumonia (CAP) patients for two respiratory fluoroquinolones: levofloxacin and moxifloxacin [Abstract]. American Society of Health-System Pharmacists (ASHP), Las Vegas, NV, December 2007.
  32. Sikirica V, Janagap C, Schein JR, Olson W, Doshi D, Crown WH (non-Premier authors). Cost and outcomes associated with levofloxacin and moxifloxacin in hospitalized community-acquired pneumonia (CAP) patients [Abstract]. American Society of Health-System Pharmacists (ASHP), San Francisco, CA, June 2007.
  33. Turpin RS, Mahmoud N, Yang G, Saunders W. Length of stay and costs associated with surgical site infections in colon procedures in a large U.S. database [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, May 2007. [Abstract: Value Health 2007; 10(3): A162.]
  34. Wood C, Rajagopalan S, Shivaprakash M, Chandwani S, Turpin RS (non-Premier authors). Mortality, hospital stay, and costs associated with candidemia after major esophagus, stomach, and bowel procedures in US hospitals. Infect Dis Clin Pract 2009; 17(5): 306-8

MEDICAL IMAGING

     
  1. Goldman JH, Main ML, Exuzides A, Colby C, Feinstein S, Waaler A, Grayburn P (non-Premier authors). Perflutren protein-type a microspheres injectable suspension,USP does not increase mortality in critically ill patients: preliminary results from a retrospective matched case-control study [Abstract]. European Association of Echocardiography (EUROECHO), Madrid, Spain, December 2009 [Eur J Echocardiogr 2009: 10(Suppl 2): ii4].
  2. Jassak S, Lunacsek O, Patel P, Shah M (non-Premier authors). Volume and mix of cardiac x-ray procedures across US hospitals: utilization data to support financial decisions [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Ontario, Canada, May 2008 (Value Health 2008; 11(3): A203).
  3. Main ML, Exuzides A, Colby C, Feinstein S, Goldman J, Waaler A, Grayburn P (non-Premier authors). Perflutren protein-type a microspheres injectable suspension,USP does not increase mortality in critically ill patients: preliminary results from a retrospective matched case-control study [Abstract]. European ISPOR, Paris, France, October 2009 [Value Health 2009; 12(7): A320]
  4. Main ML, Exuzides A, Colby C, Feinstein S, Goldman J, Waaler A, Grayburn P (non-Premier authors). Optison™ does not increase mortality in critically ill patients: preliminary results from a retrospective matched case-control study [Abstract]. American College of Cardiology (ACC), Atlanta, GA, March 2009 [J Am Coll Cardiol 2009: 53(10): A255].
  5. Main ML, Ryan AC, Davis TE, Albano MP, Kusnetsky LL, Hibberd M. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: multicenter registry results in 4,300,966 consecutive patients. J AM Coll Cardiol (JACC) 2008; 102: 1742-6.
    View abstract
  6. Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M. Survival in an intensive care unit population undergoing transthoracic echocardiography with and without perflutren containing ultrasound contrast agents: results in 39,189 propensity matched cases [Abstract]. American College of Cardiology (ACC), Orlando, FL, March 2009 (Accepted).
  7. Min J, Ryan A, Lin FY, Davis T. In-hospital hemodialysis and mortality rates in individuals undergoing invasive cardiac catheterization procedures with low osmolar contrast agents: a multicenter study of 207,826 patients [Abstract]. American College of Cardiology (ACC), Atlanta, GA, March 2010.

METHODOLOGY

  1. Balent J. How to be an organized SAS programmer [Paper]. SAS Global Forum, Seattle, WA, April 2010.
  2. Ernst FR, Davis TE, Ryan AC, Stemkowski S. Linkage of a multi-hospital database to health plan claims data for continuum of care outcomes research [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL, May 2009. [Value Health 2009; 12(3): A24].
    View poster
  3. Ernst FR. “Healthcare Cost and Utilization Project Databases (HCUP).” In: Arnold RJ, Mast O, Eds. Reliability and Validity of Data Sources for Disease and Health Management – Report of the ISPOR Disease & Health Management Special Interest Group. Lawrenceville, NJ: ISPOR. 2010 (In press).
  4. Exuzides A, Colby C, Goldman J, Waaler A (non-Premier authors). Reducing bias in a retrospective case-control study: an application of propensity score matching [Abstract]. European ISPOR, Paris, France, October 2009. (Best poster award) [Value Health 2009; 12(7): A388]
  5. Henk H, McDonald HP, Borah BJ, Nelson M (non-Premier authors). Evaluation of continuity of care between inpatient and outpatient settings via administrative claims databases using the example of VTE prophylaxis in total hip and total knee replacement. [Workshop W34]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL, May 2009.
  6. Johnson B. %TABLEMAKER: Data Reporting Made Easy [Paper]. PharmaSUG, Orlando, FL, May 2010.
  7. Yang G, Stemkowski S, Ernst FR. Efficiency of hybrid application of exact covariate matching and propensity score [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Ontario, Canada, May 2008. [Value Health 2008; 11(3): A182-3].
  8. Yang G, Stemkowski S, Saunders W. A review of propensity score application in healthcare outcome and epidemiology [Paper]. Pharma SAS User Group International (PharmaSUG), Denver, CO, June 2007.
  9. Yang G, Stemkowski S. Application of an exact covariate matching macro in outcome analysis [Paper]. Southeastern SAS User Group International (SESUG), Hilton Head, SC, November 2007.

MULTIPLE SCLEROSIS

  1. Ernst FR, Pocoski J, Cutter G, Preblick, Kaufman D, Golub H, Knappertz V. Multiple sclerosis related in-hospital mortality: rates, age of death, and diagnoses [Abstract]. Americas Committee on Treatment and Research in Multiple Sclerosis (ACTRIMS), San Antonio, TX, June 2010.
  2. Ernst FR, Pocoski J, Cutter G, Preblick, Kaufman D, Golub H, Knappertz V. Multiple sclerosis related in-hospital mortality and principal diagnoses by age [Abstract]. European Neurological Society (ENS), Berlin, Germany, June 2010.

NEUROLOGICAL DISORDERS

  1. Blanchette CM, Stemkowski S, Craver C, Wang PF, Saunders W. Hospital length of stay associated with anticonvulsant utilization by patients with seizure disorders in the US patients [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2006, Philadelphia, PA [Value Health 2006; 9(3): A80]
  2. Holdridge KC, Saunders WB, Hornbuckle K, Polzer J, Jones ME, Houston J, Sorsaburu S. Characteristics and outcomes in hospitalized patients treated with intramuscular antipsychotics: analysis if a US hospital database [Abstract]. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ISPE), Copenhagen Denmark, August 2008.
    View abstract
  3. Stensland MD, Liu L (non-Premier authors). Cost of psychiatric hospitalizations in the United States in 2006 [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Ontario, Canada, May 2008. [Value Health 2006; 11(3): A122-3].
  4. Stensland MD, Peng X (non-Premier authors). Continuity of Care Following Hospitalization for Bipolar Disorder in Private Payer Claims [Poster]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL, May 2009 [Value Health 2009; 12(3): A189]
  5. Strutton DR, Gutierrez B, Blanchette CM. Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia. Am J Health-Syst Pharm 2008; 65(1): 42-8.
  6. Wang PF, Zhao Z, Cooper L, Gaylord B, Gutierrez B. Risk of Rehospitalization: Olanzapine versus Quetiapine [Abstract]. American Psychiatric Association(APA), New York, NY, May 2004.
  7. Wang PF, Zhao Z, Cooper L, Gaylord B, Gutierrez B. Risk of Rehospitalization: Olanzapine versus Quetiapine [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, May 2004.
  8. Wang PF, Zhao Z, Cooper L, Gaylord B, Gutierrez B. Risk of Rehospitalization: Olanzapine versus Quetiapine [Abstract]. College of Psychiatric and Neurologic Pharmacists (CPNP), Chicago, IL, April 2004.
  9. Wang S, Lasky T, Ernst FR, Greenspan J, Gonzalez L. Patterns of atypical antipsychotic use among pediatric inpatients [Podium]. International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE/ISPE), Brighton, England, UK, August 2010 (Accepted).

ONCOLOGY (See also HEMATOLOGY)

  1. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs of chemotherapy-induced nausea and vomiting (CINV) following moderately or highly emetogenic chemotherapy administered in the US outpatient hospital setting [Abstract]. Multinational Association of Supportive Care in Cancer (MASCC), Rome, Italy, June 2009.
    View poster
  2. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs of chemotherapy-induced nausea and vomiting (CINV) following moderately or highly emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2010 [EPub ahead of Print].
  3. Eaddy M, Seal B, Tangirala M, O’Day K (non-Premier authors). The economic implications of rasburicase treatment in adult tumor lysis syndrome patients [Abstract]. ISPOR, Orlando, FL, May 2009. [Value Health 2009; 12(3): A40].

PAIN / ANALGESIA

  1. Nuyts G, Jones MP (non-Premier authors). Patient segmentation and drives of access to patient controlled analgesia [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2006, Philadelphia, PA [Value Health 2006; 9(3): A168]

PHARMACOEPIDEMIOLOGY

  1. Lasky T, Greenspan J, Ernst FR, Wang S, Gonzalez ML. Vancomycin use in children hospitalized in the United States in 2008 [Abstract]. International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE/ISPE), Brighton, England, UK, August 2010 (Accepted).
  2. Lasky T, Wang S, Ernst FR, Greenspan J, Gonzalez ML. National estimates of pediatric inpatient medication use in the US in 2008 [Abstract]. International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE/ISPE), Brighton, England, UK, August 2010 (Accepted).
  3. Liu FX, Mercaldi K, Turpin R (non-Premier authors). The utilization of parenteral nutrition in the United States [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010. [Value Health 2010; 13(3): A101]

QUALITY IMPROVEMENT

  1. Bankowitz R, Duan M, Martin J, Kroch J. Impact of present on admission (POA) flag on determining complications: initial experience using a large all payor discharge abstract database [Podium]. AcademyHealth, Chicago, IL, June 2009.
    View abstract
  2. Belk K, Bankowitz R, Kroch E. Determining drivers of excess mortality in an improvement collaborative of acute care hospitals [Abstract]. AcademyHealth, Chicago, IL, June 2009.
  3. Belk K, Craver C. Evaluating the HQID hospital performance effect in the QUEST initiative [Abstract]. AcademyHealth, Boston, MA, June 2010.
  4. Belk K, Kroch E. Examining drivers of excess mortality in an improvement collaborative of acute care hospitals [Abstract]. AcademyHealth, Boston, MA, June 2010.
  5. Belk K, Lloyd D. CMS hospital acquired conditions: accuracy and completeness of POA coding [Abstract]. AcademyHealth, Chicago, IL, June 2009.
    View abstract
  6. Belk K, Lloyd D. Examining opportunities for reducing Medicare cost through lowered complications [Abstract]. AcademyHealth, Boston, MA, June 2010.
  7. Belk K, Lloyd D. The business case for fighting nosocomial infections [Abstract]. AcademyHealth, Chicago, IL, June 2009.
    View poster
  8. Craver C, Martin J, Bankowitz R, Nelson E. Validating patient harm identified using automated data streams [Abstract]. AcademyHealth, Chicago, IL, June 2009.
    View poster
  9. Craver C, Martin J, Bankowitz R, Nelson E. Measurement of harm using an automated tool and electronic data [Abstract]. National Forum on Quality Improvement in Health Care. Nashville, TN, December 2008.
  10. Craver C. Validation of automated hospital acquired infections measures [Abstract]. AcademyHealth, Boston, MA, June 2010.
  11. Duan M, Kroch E, Martin J. The challenge of modeling acute inpatient readmissions [Abstract]. AcademyHealth, Boston, MA, June 2010.
  12. Duan M, Martin J. Assessing the Premier-CareScience risk adjusted mortality in the newborn population [Abstract]. AcademyHealth, Chicago, IL, June 2009. 
    View poster
  13. Duseja R, Nsa W, Belk K, Schwartz S, Bratzler D. Does pay for performance lead to potential misuse of antibiotics among patients with congestive heart failure? [Abstract]. AcademyHealth, Boston, MA, June 2010.
  14. Kroch E, Belk K, Lloyd D. Does P4P discriminate against hospitals that serve vulnerable populations? [Abstract]. AcademyHealth, Boston, MA, June 2010.
  15. Kroch E, Buckle J, Belk K. Creating an effective performance assessment tool [Podium]. National Forum on Quality Improvement in Health Care, Nashville, TN, December 2008.
  16. Kroch EE, Johnson M, Martin J, Duan M. Making hospital mortality measurement more meaningful – incorporating advance directives and palliative care designations. Am J Med Qual (AJMQ) 2010; 25(1): 24-33.
  17. Kroch E, Sinclair S, Johnson M, Reyna K, Martin J, Duan M. Meaningful hospital mortality measurement [Podium]. AcademyHealth, Washington, DC, June 2008.
  18. Martin J, Bankowitz R, Kroch E, Duan M. Realistic Observed to Expected (O/E) Ratios and Volume Issues [Abstract]. AcademyHealth, Washington, DC, June 2008.

RESPIRATORY DISEASE

  1. Bhatia J, Saunders WB, Friedlich P, Lavin PT, Sekar KC, Ramanathan R. Differences in mortality among infants treated with three different natural surfactants for respiratory distress syndrome [Abstract]. International Workshop on Surfactant Replacement, Ancona, Italy, June 2007. (Neonatology 2007; 914: 324)
  2. Bhatia J, Saunders WB, Friedlich P, Lavin PT, Sekar KC, York JM, Lugo JP, Ramanathan R. Differences in mortality among infants treated with three different natural surfactants for respiratory distress syndrome [Abstract]. Pediatric Academic Societies (PAS), Toronto, Canada, May 2007.
  3. Lindenauer PK, Pekow P, Gao S, Crawford AS, Gutierrez B, Benjamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006; 144: 894-903.
  4. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. (non-Premier authors). Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010; 303(23): 2359-67.
    5. Linde-Zwirble W, Bloom J, Mecca R, Hansel D (non-Premier authors). Mechanical ventilation after 48 hours post surgery: evaluation of an outcome measure for severe post-operative pulmonary complications [Abstract]. AcademyHealth, Boston, MA, June 2010.
  5. Ramanathan R, Saunders WB, Lavin PT, Sekar KC, Ernst FR, Bhatia J. Mortality differences among preterm infants treated with three different natural surfactants: analyses from a large national database [Abstract]. American Academy of Pediatrics (AAP), San Francisco, CA, October 2007.
  6. Ramanathan R, Saunders WB, Lavin PT, Sekar KC, Ernst FR, Bhatia J. Mortality differences among preterm neonates treated with three different natural surfactants: analyses from a large national database [Abstract]. European Society for Paediatric Research (ESPR), Prague, Czech Republic, October 2007. (Acta Paediatrica 2007; 96 (s456): 107)
  7. Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials [Review]. J Perinatology 2009; 29: S38–S40.
  8. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK (non-Premier authors). Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010; 303(20): 2035-42.
  9. Sekar KC, Bhatia J, Ernst FR, Saunders WB, Lavin PT, Ramanathan R. Hospital costs and length-of-stay in preterm infants with respiratory distress syndrome treated with one of three different natural surfactants: analyses using a large hospital discharge database [Abstract]. American Academy of Pediatrics (AAP), San Francisco, CA, October 2007.
  10. Sekar KC, Bhatia J, Ernst FR, Saunders WB, Lavin PT, Ramanathan R. Resource use in preterm neonates with respiratory distress syndrome treated with one of three different natural surfactants: analyses using a large hospital discharge database [Abstract]. European Society for Paediatric Research (ESPR), Prague, Czech Republic, October 2007. (Acta Paediatrica 2007; 96 (s456): 109)
  11. Sekar KC, Ernst FR, Bhatia J, Ramanathan R. Differences in hospital length-of-stay and costs among infants treated with one of three different natural surfactants for respiratory distress syndrome [Abstract]. International Workshop on Surfactant Replacement, Ancona, Italy, June 2007.

RHEUMATOLOGY

  1. Bailey R, Bolge S, Ernst FR, Johnson B, McKenzie RS. Two year maintenance infliximab dosing and administration patterns in patients with rheumatoid arthritis [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010 (Accepted). [Value Health 2010; 13(3): A135]
  2. Bailey R, Waters H, Ernst FR, Johnson B, McKenzie RS. Maintenance infliximab dosing and administration patterns in patients with Crohn's disease [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010 (Accepted). [Value Health 2010; 13(3): A216]
  3. Baird CJ, Ernst FR, Minshall ME. The potential cost impact of using a PEG hydrogel sealant compared with surgical standard of care to prevent cerebral spinal fluid leaks after cranial surgery [Abstract]. Congress of Neurological Surgeons, New Orleans, LA, October 2009.

SEPSIS

  1. Durthaler JM, Ernst FR, Johnston JA. Managing severe sepsis: a national survey of current practices. Am J Health-Syst Pharm 2009; 66(1): 45-53.
  2. Ernst FR, Levy H, Qualy RL. Simplified pharmacoeconomics of critical care and severe sepsis. J Intensive Care Med 2007; 22(5): 283-93.
  3. Ernst FR, Stemkowski S. Increasing incidence of severe sepsis cases in a large hospital database, 2002-2006: associations with organ dysfunction type and multiplicity more than with age [Abstract]. American College of Chest Physicians (CHEST), Chicago, IL, October 2007. (CHEST 2007; 132(Suppl 4): 559S-560S) (Reviewed in Pulmonary Reviews, February 2008)
  4. Ernst FR, Viswanathan S, Vedarajan G, Kohli B, Reynolds J. Associations between hospital survival, length-of-stay, and cost outcomes and drotrecogin alfa (activated) use among patients with severe sepsis who are assigned surgical versus medical DRGs [Abstract]. American College of Surgeons (ACS) Clinical Congress, Chicago, IL, October 2006. [Value Health 2006; 9(3): A159.]
  5. Ernst FR, Zhu B. Patients receiving ICD-9-CM code 995.92 compared to other patients with severe sepsis [Abstract]. American College of Chest Physicians (CHEST), Orlando, FL, October 2006. [CHEST 2006; 130(4 Suppl): 221S-222S.]
  6. Lindenauer PK, Rothberg MB, Natahanson BH, Pekow PS, Steingrub JS. (non-Premier authors). Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. Crit Care Med 2010; [Epub ahead of print].
  7. Simsonson SG, Duling I, Pohorylo E, Yang H (non-Premier authors). Consistent association of statin medication and decreased mortality among severe sepsis patients from 2004-2006 [Abstract]. CHEST, Philadelphia, PA, October 2008.
  8. Yang H, Duling IT, Brown JS, Simonson SG (non-Premier authors). Respiratory organ dysfunction – a leading risk factor for hospital mortality in patients with severe sepsis or septic shock [Abstract]. International Symposium on Intensive Care and Emergency Medicine (ISICEM), Brussels, Belgium, March 2008. (Critical Care 2008; 12[Suppl 2]: P485).
  9. Yang H, Duling IT, Fan F, Simsonson SG (non-Premier authors). Comparison of severe sepsis patients identified by different definitions using ICD-9 codes in administrative database [Abstract]. CHEST, Philadelphia, PA, October 2008.

SURGERY/TRANSFUSIONS

  1. Baird CJ, Ernst FR, Minshall ME. The potential cost impact of using a PEG hydrogel sealant compared with surgical standard of care to prevent cerebral spinal fluid leaks after cranial surgery [Abstract]. Congress of Neurological Surgeons, New Orleans, LA, October 2009 (Accepted).
  2. Blanchette CM, Joshi AV, Szpalski M, Gunzburg R, Du Bois M, Donceel P, Saunders WB. Comparison between spinal surgery blood transfusion services costs and associated treatment practices in the United States and Belgium. Curr Med Res Opin 2007; 23(11): 2793-2804 (doi: 10.1185/030079907x233421).
  3. Blanchette CM, Wang P, Joshi A, Asmussen M, Saunders W, Kruse P. Cost and utilization of blood transfusion associated with spinal surgeries in the United States. Eur Spine J 2007; 16(3): 353-63
  4. Delaney CP, Chang E, Senagore AJ, Broder M (non-Premier authors). Clinical outcomes and resource utilization associated with laparoscopic and open colectomy using a large national database. Ann Surg 2008; 247(5): 819-24.
  5. Forrest MT, Punzo AJ, Szczukowski M (non-Premier authors). Cardiopulmonary complications of simple reinfusion device post knee replacement [Abstract]. American College of Chest Physicians (CHEST), San Diego, CA, November 2009.
  6. Hashemi L, Morseon M, Minshall M (non-Premier authors). The incidence and cost of hernia repair with and without surgical complications in the USA: a study using the Premier Perspective™ Database (PPD) [Abstract]. American college of Surgeons (ACS), Washington, DC, October 2010 (Accepted).
  7. Iyer S, Saunders WB, Stemkowski S. Economic burden of postoperative ileus associated with colectomy in the United States. J Managed Care Pharm (JMCP) 2009; 15(6): 485-94.
  8. Jallo J, Ernst FR, Minshall ME. The cost of cerebral spinal fluid leaks after spinal surgery in the USA [Abstract]. Congress of Neurological Surgeons, New Orleans, LA, October 2009.
  9. Kaplan N, Stemkowski S, Ramos J. Early intervention of negative pressure wound therapy utilizing vacuum assisted closure in trauma patients: impact on hospital length of stay & cost. Adv Skin Wound Care 2009; 22(3): 128-32.
  10. Krishnan S, Conner TM, Leslie R, Stemkowski S, Shander A.Shander A.  Choice of hemostatic agent and hospital length of stay in cardiovascular surgery. Semin Cardiothorac Vasc Anesth 2009; 13(4): 225-230.
  11. Lerner J, Engelhart L, Kozma C, Slaton T (non-Premier authors). Costs of vertebroplasty and kyphoplasty from the hospital perspective [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010. [Value Health 2010; 13(3): A127]
  12. Mahmoud NN, Turpin RS, Yang G, Saunders WB. Impact of surgical site infections on length of stay and costs in selected colorectal procedures. Surg Infect (Larchmt) 2009; 10(6): 539-44.
  13. Minshall ME, Jallo J, Ernst FR. The potential cost impact of using a PEG hydrogel sealant compared with fibrin sealant to prevent cerebral spinal fluid leaks after spinal surgery. North American Spine Society (NASS), Orlando, FL, October 2010 (Accepted).
  14. Narayan S, Stemkowski S, Conner T, Tucker M, Shander A. A comparison of costs associated with spinal surgeries by choice of hemostatic agent [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Ontario, Canada, May 2008. [Value Health 2008; 11(3): A241].
  15. Narayan S, Stemkowski S, Conner TM, Tucker M, Shander A. A comparison of cardiac surgeries by choice of fibrin agent [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Ontario, Canada, May 2008. [Value Health 2008; 11(3): A241].
  16. Nasciben V, Rupprecht F, Moore M, Gunnarsson C (non-Premier authors). The economic impact of contour versus hand sewn suture and other mechanical staples in low anterior resections of colon rectal cancer surgery: interim results using real world data from Premier’s hospital database [Abstract] International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA, May 2010. [Value Health 2010; 13(3): A49]
  17. Mahmoud NN, Turpin RS, Yang G, Saunders WB. Impact of surgical site infections on length of stay and costs in selected colorectal procedures. Surg Infect (Larchmt) 2009; 10(6): 539-44.
  18. Saunders WB, Wang PF, Gaylord B. Elective Surgeries in the US: Risk Factors, Cost, and Outcomes [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Washington, DC, May 2005.
  19. Zhang B, Menzin J, Tran MH, Neumann PJ, Friedman M, Sussman M, Hepner D (non-Premier authors). The potential savings in operating room time associated with the use of Sugammadex to reverse selected neuromuscular blocking agents: findings from a hospital efficiency model [Abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Ontario, Canada, May 2008 (Value Health 2008; 11(3): A244).

Home | Reducing Costs | Improving Quality & Safety | Managing Risk | About Premier